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Abstract: Trans-1-amino-3-18F-fluorocyclobutanecarboxylic-acid (anti-[18F]-FACBC) has been
approved for the detection of prostate cancer (PCa) in patients with elevated prostate-specific-antigen
following prior treatment. This review and meta-analysis aimed to investigate the diagnostic
performance of 18F-FACBC positron emission tomography/computed-tomography (PET/CT) in the
detection of primary/recurrent PCa. A bibliographic search was performed including several databases,
using the following terms: “FACBC”/“fluciclovine” AND “prostate cancer”/“prostate” AND
“PET”/“Positron Emission Tomography”. Fifteen and 9 studies were included in the systematic reviews
and meta-analysis, respectively. At patient-based analysis, the pooled sensitivity and specificity
of 18F-FACBC-PET/CT for the assessment of PCa were 86.3% and 75.9%, respectively. The pooled
diagnostic odds-ratio value was 16.453, with heterogeneity of 30%. At the regional-based-analysis,
the pooled sensitivity of 18F-FACBC-PET/CT for the evaluation of primary/recurrent disease in the
prostatic bed was higher than in the extra-prostatic regions (90.4% vs. 76.5%, respectively); conversely,
the pooled specificity was higher for the evaluation of extra-prostatic region than the prostatic bed
(89% vs. 45%, respectively). 18F-FACBC-PET/CT seems to be promising in recurrent PCa, particularly
for the evaluation of the prostatic bed. Additional studies to evaluate its utility in clinical routine
are mandatory.
Cancers 2019, 11, 1348; doi:10.3390/cancers11091348 www.mdpi.com/journal/cancers
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1. Introduction
Prostate cancer (PCa) is the most frequently detected type of cancer in men and constitutes a
major healthcare problem in developed countries [1], remaining the second most common cause of
cancer-related death in the Western world [2].
Following initial diagnosis, the majority of men receive several treatments, such as usually a
radical prostatectomy ± lymphadenectomy or radiation/brachytherapy in case of localized disease,
and systemic therapy in case of widespread disease. Relapse remains common despite advances in
primary treatment and improved overall survival (OS) with a biochemical recurrence developing in
20% to 40% of patients [3–6].
The management of primary and recurrent PCa patients has been completely changed after the
inclusion of new imaging modalities, such as magnetic resonance imaging (MRI) and positron emission
tomography (PET). MRI is a well-documented method to evaluate the extension of the primary tumor
and to detect and localize recurrent cancer within the prostate [7–9]. However, routine multiparametric
(mp) MRI is still limited by its poor specificity to differentiate significantly from indolent PCa [10].
In the last 10 years, PET/computed tomography (PET/CT) has gained an important role in the
evaluation of patients with PCa. Radiolabeled choline PET/CT has demonstrated the ability to detect the
presence of early recurrence of disease when conventional imaging resulted negative [11]. Furthermore,
the recent introduction of radiolabeled prostate specific membrane antigen (PSMA), like 68Ga-PSMA
and 18F-PSMA, has significantly improved the detection rate, also in case of early recurrence of disease
(such as a prostate-specific antigen (PSA) <0.5 ng/mL) [12].
Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-[18F]-FACBC) is an amino acid PET
tracer that has shown to be promising for visualizing PCa. This tracer was developed for L-amino acid
transport evaluation; it demonstrated favorable dosimetry with the liver being the critical organ [13].
Its safety, tracer stability, and uptake kinetics in patients have been reported in a phase I trial [14].
Nowadays, 18F-FACBC is approved by the Food and Drug Administration (FDA) and the European
Commission (EC) to detect PCa in patients with elevated PSA following prior treatment. Approval
was based on encouraging diagnostic performance and histologically confirmed data on patients with
biochemical recurrence [15]. Recently it was included in the National Comprehensive Cancer National
(NCCN) guidelines for the management of recurrent PCa patients.
Until now, few pooled data have been published about the role of 18F -FACBC PET/CT in patients
with PCa. Ren et al. [16] collected data from six studies, published between 2011 and 2014 and including
251 patients that concluded for a good sensitivity of 18F -FACBC PET/CT for the detection of PCa
recurrence. In 2015, Yu et al. [17] published a critical analysis of the available tracers for PET/CT in PCa,
collecting data for 18F -FACBC from five studies (n = 84 subjects), showing a limited detection rate of
this imaging technique for the recurrence of post-prostatectomy PCa (detection rate = 40%). However,
in May 2016, 18F -FACBC PET/CT received the approval by the Food and Drug administration for use
in patients with suspected recurrent PCa [18]. In the last years, many prospective and retrospective
experiences have been performed, and therefore, a new update of the recent findings seems necessary,
not only in the restaging but also in the initial staging of disease.
Therefore, the present review and meta-analysis aimed to investigate the diagnostic performance
of 18F -FACBC in the detection of primary and recurrent PCa patients.
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2. Materials and Methods
2.1. Search Strategy and Study Selection
A bibliographic search until 30 April 2019 was performed by including the following databases:
Pubmed, Scopus, Embase, Web of Science, Cochrane library, and Google Scholar. The terms used
were “FACBC” or “fluciclovine” AND “prostate cancer” or “prostate” AND “PET” or “Positron
Emission Tomography”. The search was carried out with and without the addition of filters (such as
English language only; type of article: original article, research article; subjects: humans only). Three
reviewers (Domenico Albano, Viviana Frantelizzi and Matteo Baucknhet) performed the literature
search, and two independent reviewers (Priscilla Guglielmo and Lorenzo Fantechi) selected the study
inclusion and data extraction in duplicate. Any discrepancies were resolved by a consensus, when
necessary. All recognized records were combined, and the full texts were retrieved. Full texts were
further evaluated by four reviewers (Giovanni Argiroffi, Riccardo Laudicella, Pierpaolo Alongi and
Laura Evangelista). Moreover, a search across the databases was completed by another reviewer (Anna
Giulia Nappi) checking the references of the studies included to further improve the eligibility.
This systematic review was carried out using established methods [19], and the presentation of
results was made according to the PRISMA guidelines [20]. All studies that fulfilled the inclusion
criteria were considered eligible for the systematic review and meta-analysis: (a) a sample size
more than 10 patients; (b) the index test: 18F-FACBC PET/CT; (d) the outcomes, such as detection
rate (DR), true positive (TP), true negative (TN), false positive (FP), and false negative (FN), which
allowed us to construct 2 × 2 contingency tables. Moreover, in the case of studies that included the
same population, the report with the highest number of enrolled patients was considered for the
meta-analysis. Conversely, reviews, clinical reports, meeting abstracts, and editor comments were
excluded. The quality assessment included both the risk of bias assessment and applicability concerns
by using QUADAS-2 evaluation [21].
2.2. Data Extraction
For each included study, general information was retrieved, such as basic data (authors, journal,
year of publication, country and study design), patient characteristics (number of patients, mean or
median age, Gleason score), type of treatment, mean or median PSA value at PET time, and PSA
kinetic values.
2.3. Statistical Method
StatsDirect and Meta-Analyst (version Beta 3.13; [22]) were used to carry out the analysis.
Heterogeneity was tested using the χ2 and the I2 tests. The χ2 -test provided an estimate of the
between-study variance and the I2 test measured the proportion of inconsistency in individual studies
that cannot be explained by chance. According to Higgins et al. [19], the values of 25%, 50%, and
75% for heterogeneity (I2) were considered low, moderate, and high, respectively. In accordance with
the recommendation of the Cochrane Oral Health Group, the meta-analysis was carried out with the
random-effect model as the number of studies was equal or superior to 4.
Data on diagnostic performance such as pooled sensitivity, pooled specificity, positive and negative
likelihood ratio (LR+ and LR−), diagnostic odds ratio (DOR) with 95% confidence intervals (CIs) for
the evaluation of primary and recurrent PCa, were assessed. A patient-based and a region-based
meta-analyses were carried out in accordance with available data. Publication bias was assessed using
a funnel plot. A symmetrical plot was indicative of the absence of publication bias.
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3. Results
3.1. Search Results
The literature search revealed 40 articles published from 1 January 2007 to 30 April 2019. Reviewing
titles and abstracts, we excluded 24 articles because these did not fit with the field of interest or because
these papers were letters, editorials, reviews or due to the patient data overlap. Therefore, 15 studies
were selected and included in the systematic reviews and 9 articles were considered for the meta-analysis
(Figure 1). Also the papers by the developers of 18F-FACBC were considered [23,24].Cancers 2019, 11, x  4 of 15 
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3.2. Study Characteristics
The basics characteristics of the included studies are reported in Table 1 [15,23–36]. The number
of enrolled patients ranged from 15 to 596, and a total of 1226 PCa patients were included. The selected
articles were published by researchers from Europe, USA, and Japan. Four studies were retrospective
whereas 11 studies were prospective. 18F-FACBC PET/CT was performed in the preoperative setting in
6 studies (n = 178 patients), for the detection of recurrence in patients with biochemical relapse after
primary treatments in 8 studies (n = 1033 patients) and in both settings in 1 study (n = 15 patients).
In the restaging, the mean value of PSA ranged between 0.44 and 17.94 ng/mL.
The mean and median age of the patients ranged from 42 to 90 years. The Gleason score (GS) was
≤6 in 49 (4%) patients, 7 in 376 (30.6%) patients, ≥8 in 142 (11.6%) patients, not available in the remaining
659 (53.8%). No significant adverse effects after the administration of 18F-FACBC were reported.
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Table 1. Characteristics of selected studies.
Study Characteristics Patient Characteristics
Authors Year Journal Country Study Design Setting N. pts Mean Age(Range)
Gleason
Score (n) Type of Treatment (n)
Mean PSA
(Range)
Mean PSA
Doubling Time
(Range)
Schuster et al.
[23] 2007 JNM USA Prospective
Staging
(n = 9)
Restaging
(n = 6)
15 62y (45–76)
6 (2)
7 (2)
8 (2)
9 (2)
10 (1)
NA (6)
SP (1),
BCT + RT + CTR (1),
BCT (2),
BCT + RT (1),
RP + RT (1),
naive (9)
15 ng/mL
(1.9–71) NA
Schuster et al.
[24] 2011 Radiology USA Prospective Restaging 50
68.3y
(50–90) NA
RP (13), CTR, HFUS, EBRT,
and/or BCT (37)
6.62 ng/mL
(0.11–44.74) NA
Turkbey et al.
[25] 2014 Radiology USA Prospective Staging 21 62y (44–73)
6 (3)
7 (12)
8 (5)
9 (1)
RARP + LND (21) 13.5 ng/mL(3.55–37.3) NA
Kairemo et al.
[26] 2014
BioMed
Research
Intern
Finland Retrospective Restaging 26 * 68.1y(56–77)
5 (3)
6 (7)
7 (7)
8 (3)
9 (5)
RP + RT (12), RT (13),
ADT (20), BT (11),
CHT(5), 153Sm-EDTMP (7),
Denosumab (1)
7.9 ng/mL
(0.11–69)
positive FACBC
3.2mo (0.3–6)
negative FACBC
31.2mo (8–84)
Nanni et al. [27] 2014 ClinGenitourinCancer Italy Prospective Restaging 28
67y
(55–78)
6 (1)
7 (16)
8 (6)
9 (4)
10 (1)
RP (28),
RT (11),
ADT (14)
2.9 ng/mL
(0.2–14.6) NA
Nanni et al. [28] 2015 ClinNuclMed Italy Prospective Restaging 50 67y (55–78)
≤6 (4)
7 (31)
8–10 (15)
RP (50),
RT (23),
ADT (21)
3.2 ng/mL
(0.24–15.6) NA
Odewole et al.
[29] 2016 EJNMMI USA Retrospective Staging 53
67.57y
(49–90)
7 (49)
NA (4)
RP (7), EBRT (5),
BCT (6), CTR (4),
HT (1), 2 or more treatment
(30)
7.2 ng/mL
(0.11–44.8)
18.6mo ##
(−31.6–357.8)
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Table 1. Cont.
Study Characteristics Patient Characteristics
Authors Year Journal Country Study Design Setting N. pts Mean Age(Range)
Gleason
Score (n) Type of Treatment (n)
Mean PSA
(Range)
Mean PSA
Doubling Time
(Range)
Bach-Gansmo
et al. [15] 2017 J Urol
Norway
Italy USA Retrospective Restaging 596 67y (42–90)
6.7 (110) §
7.4 (355) §§
RP (130), RP + other but no
RT (62),
RT (76), RT + other (266),
other but no RT/RP (41)
5.43 ng/mL
(0.05–82.0) NA
Akin-Akintayo
et al. [30] 2017
ClinNucl
Med USA Prospective Restaging 42
62y
(42–75) 7 (42)
# RP (42) 2.1 ng/mL(0.07–11.15) NA
Selnaes et al. [31] 2018 EurRadiol Norway Prospective Staging 26 66.2y(55–71.9)
7 (11)
8 (8)
9 (7)
RARP + LND (26) 14.6 ng/mL(3.7–56.9) NA
Jambor et al. [32] 2018 EJNMMI Finland Prospective Staging 26 65y **(49–76)
6 (1)
7 (17)
8 (2)
9 (6)
RARP + LND (26) 12 ng/mL(4.1–35) NA
Akin-Akintayo
et al. [33] 2018
Eur J
Radiol USA Prospective Staging 24
70.8y
(60–83) 7 (24)
#
BCT (3), RT (3),
PT (1), CTR (1), CTR + HT
(1),
BCT + other treatment but
no RP (13),
other treatment but no BCT
(2)
8.5 ng/mL
(2.2–29.3) NA
Andriole et al.
[34] 2019 J Urol USA Prospective Restaging 213
66.4y
(46–90)
≤6 (27)
7 (134)
≥8 (50)
NA (2)
RP (121), RP + RT (43),
EBRT (21), BCT (1),
EBRT + BCT (2), EBRT +
ADT (17),
EBRT + CTR (2), CTR (1),
BCT + ADT (1), EBRT +
BCT + ADT (2),
HIFU (1), High-dose BCT
(1)
4.24 ng/mL
(0.2–93.5) NA
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Table 1. Cont.
Study Characteristics Patient Characteristics
Authors Year Journal Country Study Design Setting N. pts Mean Age(Range)
Gleason
Score (n) Type of Treatment (n)
Mean PSA
(Range)
Mean PSA
Doubling Time
(Range)
England et al.
[35] 2019
Clin Nucl
Med USA Retrospective Restaging 28
67.1y
(53–77)
7 (19)
8 (3)
9 (6)
Primary treatment
RP (22), RP+ EBRT (3),
RP + EBRT + ADT (1), EBRT
+ ADT (2)
Salvage therapy
RT (6), ADT (1), RT + ADT
(1), LND (1)
0.44 ng/mL
(0.1–1.0)
6.38mo
(1.6–16.8)
Suzuki et al. [36] 2019
Japanese
J Clin
Oncol
Japan Prospective Staging 28 67.9 (57–77)
<6 (1)
7 (12)
8 (8)
9 (8)
RARP + LND (28)
17.94
ng/mL
(1.20–82.38)
NA
RP = radical prostatectomy; RS = radical surgery; EBRT = external beam radiotherapy; RT = radiotherapy; ADT = androgen deprivation therapy; LND = lymph nodal dissection; HT =
hormone therapy; RARP = robot assisted radical prostatectomy; BT = bisphosphonate therapy; CHT = chemotherapy; BCT = brachitherapy; CTR = criotherapy; HFUS = high-frequency
ultrasound; SP = subtotal prostatectomy; PT = proton therapy; NA = not-available. * 1/26 patient was affected by meningioma, considered as negative; ** Median value of the initial 32
patients; § Median Gleason-score value in Recurrent Prostate Cancer; §§ Median Gleason-score value in Primary Standard of Truth; # Median Gleason-score value; ## Only for 49/53 patients.
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3.3. Methodological Quality
All 15 studies were evaluated qualitatively using the QUADAS-2 tool (Table S1; Figure 2). The risk
of bias was unclear for patient selection in 1 study, which did not provide information regarding
consecutive enrollment [15]. For the index test and reference standard, the risk of bias was low in 6
studies [24,29,31–33,36]. For flow and timing, many studies reported time intervals between PET/CT
examinations and pathological or other imaging confirmations. The applicability of the included
studies was adequate in the majority of reports, being unclear only in 1 study for the reference
standard [30].
Cancers 2019, 11, x  7 of 15 
 
3.3. Methodological Quality 
All 15 t dies were evalua ed qualitatively sing t e QUADAS-2 tool (Table S1; Figu  2). The 
risk of bias was unclear for patient s lection in 1 study, which did ot provide inf rmation regard g 
consecutive enrollment [15]. F r the index test and reference standard, the risk of bias as low in 6 
studies [24,29,31–33,36]. F r flow and timing, many studies reported time interva s between PET/CT 
examinations and pathological or other imaging confirmations. The applicability f  included 
studies was adequate in the majority of reports, being unclear only in 1 study for the reference 
standard [30]. 
 
 
Figure 2. QUADAS 2 score of all included studies. 
  
Figure 2. QUADAS 2 score of all included studies.
Cancers 2019, 11, 1348 9 of 17
3.4. Qualitative Results
PET/CT was employed in 14/15 studies, without CT contrast media injection, whereas PET/MRI
was used in 2 studies [31,32]. The injected radiopharmaceutical activity and the time between
radiotracer injection and image acquisition were similar across all studies.
Analysis of PET images was mostly performed using visual analysis; however, additional
semi-quantitative criteria, i.e., maximal standardized uptake values (SUVmax), was performed in some
reports [23,26–28]. 18F-FACBC PET/CT or PET/MRI identified the presence of PCa in prostatic and
extra-prostatic bed, such as in the regional, distant lymph nodes and bone. The DR was available in
9/15 studies. It ranged between 36% and 90%, being different in accordance with PSA serum levels
(Table 2). Andriole et al. [34] demonstrated that DR was broadly proportional to pre-scan PSA: lesions
were detected in 79% patients with PSA ≥ 1.0 ng/mL and in 84% with PSA ≥ 2.0 ng/mL. On the other
side, some authors found that there was no statistically significant difference in the PSA values and PSA
doubling-time (PSAdt) between patients with positive and negative findings [26,35]. England et al. [35]
reported that the DR was significantly higher for patients with GS > 7 than those with a score equal
to 7.
The performance of 18F-FACBC PET/CT was different based on the phase and the site of PCa
(Table 3). In particular, in the initial staging, the sensitivity for the primary and lymph nodes metastasis
was 71% [32] and 67% [36], respectively. In the restaging setting, the sensitivity for the prostatic bed
and extra-prostatic bed recurrence was 89% [24] and 90% [15], respectively. Interestingly, in the study
by Turkbey et al. [25], 18F-FACBC uptake in tumors was similar to that in benign prostatic hyperplasia
(BPH). However, Jambor et al. [32] reported that SUVmax in the primary tumor was statistically
significantly higher for patients with GS > 7 than GS = 6 or BPH, thus underlying the importance of
the patient selection.
Akin-Akintayo et al. [33] compared 18F-FACBC PET/CT with mpMRI in patients with recurrent PCa
showing a higher detection for the first modality (overall 94.7% vs. 36.8%); Turkbey et al. [25], instead,
performed a sector-based comparison with histopathologic analysis in patients with a recent diagnosis
of PCa, revealing lower sensitivity and specificity for 18F-FACBC PET/CT than for T2-weighted
imaging (67% and 66% vs. 73% and 79%, respectively), but combined modalities achieved a positive
predictive value of 82% for tumor localization, which was higher than that with either modality alone.
Another study proved higher positivity rates with 18F -FACBC PET/CT than enhanced CT at all PSA
levels, PSAdt and GS in patients with suspected recurrent PCa [29]. Furthermore, the performance
of 18F-FACBC PET/CT was superior to those of 111In-capromab SPECT/CT regarding sensitivity for
prostatic and extra-prostatic bed (89% vs. 69% and 100% vs. 10%, respectively) [24]. Finally, two studies
directly compared 18F-FACBC with 11C-Choline PET/CT, demonstrating a greater detection rate for
18F-FACBC than 11C-Choline, either on a patient- and a lesion-based analysis and despite the PSA
serum levels [27,28].
The change of management with 18F-FACBC PET/CT was reported by Andriole et al. [34], in 122
out of 213 patients (56%); the most frequent change was to withhold planned salvage or non-curative
systemic therapy in favor of watchful waiting. Moreover, Akin-Akintayo et al. [30] demonstrated that
18F-FACBC PET/CT was able to modify the radiotherapy field and overall radiotherapy decision in
40.5% of patients with post-prostatectomy recurrent PCa.
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Table 2. The selection of the studies.
Author, (Ref) Year Journal Country N pts Outcome DR TP TN FP FN
Schuster et al. [23] 2007 JNM USA 9 Accuracy LN (patient-based) NA 2 5 0 2
Schuster et al. [24] 2011 Radiology USA 50
Accuracy (PB) FACBC (region-based)
NA
32 8 4 4
Acc (extra-p) FACBC (region-based) 10 7 0 0
Acc (PB) Capromab (region-based) 25 7 5 11
Ac (extra-p) Capromab (region-based) 1 7 0 9
Turkbey et al. [25] 2014 Radiology USA 21
DR for primary
19/21 (90%)Lesion-based 33 0 38 15
Accuracy MRI (les-based) 34 0 21 14
Kairemo et al. [26] 2014
BioMed
Research
Intern
Finland 26 **
DR 17/26 (65%)
Patient-based 11 12 3 0
Nanni et al. [27] 2014 ClinGenitourinCancer Italy 28 DR (comparison with Choline) 10/28 (36%) NA NA NA NA
Nanni et al. [28] 2015 ClinNucl Med Italy 50 DR (comparison with Choline) 17/50 (34%) NA NA NA NA
Odewole et al. [29] 2016 EJNMMI USA 53
DR (all PSA levels and clinical data)
41/53 (77.4%)
Accuracy (PB) FACBC 31 9 7 4
Accuracy (PB) CT 4 14 2 31
Accuracy (extra-pr) FACBC 12 15 0 15
Accuracy (extra-pr) CT 3 15 0 23
Bach-Gasmo et al.
[15] 2017
J Urol
Norway
Italy
USA
596
DR
403/595 (67.7%)
Lesion-based 153 216 93 91
Region-based (PB) 74 14 20 10
Region-based (Extra-prost) 36 1 3 4
Patient-based 98 14 21 10
Akin-Akintayo et al.
[30] 2017 ClinNucl Med USA 42 DR (change in radiotherapy strategy) 34/42 (81%) NA NA NA NA
Selnaes et al. [31] 2018 EurRadiol Norway 26
Accuracy for LN NA
Patient-based NA 4 16 0 6
Region-based NA 6 185 0 14
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Table 2. Cont.
Author, (Ref) Year Journal Country N pts Outcome DR TP TN FP FN
Jambor et al. [32] 2018 EJNMMI Finland 26
Accuracy LN
NAPatient-based 7 19 0 0
Region-based NA NA NA NA
Akin-Akintayo et al.
[33] 2018
Eur J Radiol USA 24
Accuracy (PB) FACBC *
NA
13 1 8 0
Accuracy (PB) MRI * 5 5 4 8
Accuracy (extra-p) FACBC 7 9 1 1
Accuracy (extra-p) MRI * 4 7 3 4
Andriole et al. [34] 2019 J Urol USA 213 DR (also for PSA level) 122/213 (57%) NA NA NA NA
England et al. [35] 2019 ClinNucl Med USA 28 DR (for site and clinical data) 13/28 (46%) NA NA NA NA
Suzuki et al. [36] 2019 Japanese J
ClinOncol
Japan 28
Accuracy LN
NAPatient-based 4 19 3 2
Lesion-based 4 28 5 3
DR = detection rate; NA = not available; LN = lymph node; PB = prostatic bed; * M1 reader; ** 1/26 patient affected by meningioma was considered as negative.
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Table 3. Accuracies based on the study setting and the type of analysis.
Type of Analysis Study Name (Year), Ref Setting (Site) TP FN TN FP Sensitivity Specificity
Patient-based analysis
Suzuki et al. (2019), [36] Staging (LN) 4 2 19 3 66.6% 86.3%
Selnaes et al. (2018), [31] Staging (LN) 4 6 16 0 45% 80.8%
Jambor et al. (2018), [32] Staging (primary) 7 0 19 0 70.6% 82.8%
Bach-Gasmo et al. (2017), [15] Restaging (all) 98 10 14 21 90.7% 40%
Kairemo et al. (2014), [26] Restaging (all) 11 0 12 3 76.2% 68%
Schuster et al. (2007), [23] Staging/restaging (all) 2 2 5 0 50% 66.7%
Region-based analysis (PB)
Schuster et al. (2011), [24] Restaging 32 4 8 4 88.9% 66.7%
Bach-Gasmo et al. (2017), [15] Restaging 74 10 14 20 88.1% 41.2%
Akin-Akintayo et al. (2018), [33] Staging 13 0 1 8 78.3% 31.6%
Odewole et al. (2016), [29] Staging 31 4 9 7 88.6% 56.3%
Region-based analysis (extra-PB)
Schuster et al. (2011), [24] Restaging 10 0 7 0 75% 70.6%
Bach-Gasmo et al. (2017), [15] Restaging 36 4 1 3 90% 25%
Akin-Akintayo et al. (2018), [33] Staging 7 1 9 1 87.5% 90%
Odewole et al. (2016), [29] Staging 12 15 15 0 45.9% 80%
LN = lymph node; TP = true positive; FN = false negative; TN = true negative; FP = false positive.
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3.5. Quantitative Results
In accordance with the inclusion criteria, the quantitative assessment was available in 9
studies [15,23,24,26,29,31–33,36] (Table 4). At patient-based analysis (n = 6 studies), the pooled
sensitivity and specificity of 18F-FACBC PET/CT scan for the assessment of primary and recurrent PCa
were 86.3% (95% CIs: 79.6–91.4%) and 75.9% (66.9–83.5%) with an heterogeneity of 78.6% and 88.7%
(both p <0.0001), respectively. Moreover, the pooled DOR value was 16.453 (95% CI: 5.241–51.646),
with heterogeneity of 30%. At the regional based-analysis (n = 4 studies), the pooled sensitivity
of 18F-FACBC PET/CT for the evaluation of primary and recurrent disease in the prostatic bed was
higher than that in the extra-prostatic regions (90.4% vs. 76.5%, respectively); conversely, the pooled
specificity was higher for the evaluation of extra-prostatic region than the prostatic bed (89% vs. 45%,
respectively). Furthermore, LR+ was high in the extra-prostatic region, while LR- was low in prostatic
bed, with heterogeneity of 0%. No asymmetry in the forest plot was found; therefore, no publication
bias was present across the studies.
Table 4. The pooled diagnostic performance for 18F-FACBC (independently from the clinical setting
and site).
Meta-Analysis
Results
Patient-Based Analysis
(95% CI)
Region-Based Analysis
(PB) (95% CI)
Region-Based Analysis
(ex-PB) (95% CI)
Value I2 Value I2 Value I2
Pooled sensitivity, % 86.3%(79.6–91.4%) 78.6%
90.4%
(84.8–94.4%) 22.1%
76.5%
(66–85%) 87.3%
Pooled specificity, % 75.9%(66.9–83.5%) 88.7%
45.1%
(33.2–57.3%) 63.3%
88.9%
(73.9–96.9%) 78.7%
DOR 16.453(5.241–51.646) 29.9%
8.026
(3.841–16.769) 3.5%
24.820
(3.777–163.12) 36%
LR+ 4.557(1.685–12.324) 72.9%
1.598
(1.088–2.349) 70%
6.024
(0.568–63.943) 85.6%
LR− 0.337(0.166–0.681) 63.6%
0.221
(0.130–0.375) 0%
0.251
(0.058–1.090) 71.6%
PB = prostatic bed; PPV = positive predictive value; NPV = negative predictive value; DOR = diagnostic odds ratio;
LR = likelihood ratio; IC = interval of confidence; I2 = inconsistency.
4. Discussion
As previously mentioned, the meta-analysis from Ren et al. [16] reported that 18F-FACBC PET/CT
had a high sensitivity (pooled sensitivity = 87%) and a moderate specificity (pooled specificity = 66%),
therefore it can be considered an useful non-invasive, metabolic imaging technique for the diagnostic
workup of PCa relapse. In the present meta-analysis, performed in 1226 PCa, the pooled sensitivity
and specificity were 86% and 76% respectively, thus showing a slight increase for the specificity.
Furthermore, in the analysis by Yu et al. [17], FACBC showed a detection rate ranged between
22% and 61% for prostatic disease and between 19% and 33% for extra-prostatic disease, in accordance
with the primary treatments (radical prostatectomy or radiotherapy). In our meta-analysis, we did not
evaluate the pooled detection rate, but we calculated the pooled sensitivity and specificity. As illustrated
in Table 4, the sensitivity of 18F-FACBC was equal to 90% for the identification of disease in the
prostatic bed and 77% for extra-prostatic organs.
However, in the last years, PSMA-PET has rapidly been introduced in clinical practice for the
management of patients with recurrent PCa, particularly in case of low PSA levels [37]. Already,
the study by Yu C-Y et al. [17] reported that 18F-FACBC, Choline and Acetate-PET have similar
detection rate for overall site of disease after radical prostatectomy or radiotherapy (ranged between
40% and 81%), but PSMA was able to reach a detection rate ranged between 82% and 96% in the
same setting.
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Two recent papers about a head-to-head comparison between 18F-FACBC and 68Ga-PSMA PET/CT
have been published. The data are controversial. In the study by Pernthaler et al. [38] involving 58
patients with recurrent PCa with a PSA level ranged between 0.2 and 230 ng/mL, 18F-FACBC detected
more accurately the presence of a local recurrence than 68Ga-PSMA, due to its favorable biodistribution.
Furthermore, the authors found that 18F-FACBC is almost equivalent to 68Ga-PSMA-11 in detecting
distant metastases of PCa recurrence. Conversely, in the study by Calais et al. [39] enrolling 50 patients
with recurrent PCa, the detection rate of PSMA-PET was significantly higher than 18F-FACBC (56% vs.
26%, respectively) in case of a PSA level <1 ng/mL. However, the authors found that the detection
rate for the local recurrence was higher for 18F-FACBC than 68Ga-PSMA PET/CT (38% vs. 14%,
respectively). The missing data about the diagnostic performance, in terms of sensitivity and specificity
in both the above-mentioned papers, represent a great limitation for the final conclusion on “the best
radiopharmaceutical agent”. A recent paper by Lawhn-Heath et al. [40] reported that the sensitivity
and specificity of 68Ga-PSMA-11 for recurrent PCa are equal to 89.1% and 31.2%, thus registering a
high rate of false positivity.
From the present systematic review and meta-analysis arise some considerations:
1. 18F-FACBC is more performant than 111In-capromab SPECT/CT and 11C-Choline for the detection
of PCa recurrence. Therefore, if available it should be preferred in patients with a PSA increase,
after primary treatments. However, data about the comparison with 18F-Choline PET/CT are
missing and should be explored, also considering the radioisotope properties.
2. The combination of 18F-FACBC PET/CT with mpMRI (or with a PET/MRI) seems useful for the
detection of primary PCa, and therefore, it would be suggested in case of undetectable tumors in
patients with a negative biopsy but a persistent PSA level increase. However, the interpretation
of this sophisticated imaging required a great experience and a significant learning curve.
3. The sensitivity for the evaluation of lymph node metastasis in the initial staging of disease is
moderate (45%–66%; [31,36]), like for the other radiopharmaceuticals (radiolabeled PSMA and
Choline; [41,42]). Probably the recent introduction of new imaging modalities, such as digital
PET/CT or PET/MRI that has a higher spatial resolution, would improve the pathological lymph
node detection.
4. The pooled sensitivity for the identification of recurrence in prostate bed is high, being >90% with
a limited pooled specificity (about 45%), probably due to the FP findings in case of inflamed cells,
as reported by Oka et al. [43]. However, the absent uptake of radiopharmaceutical in the bladder
represents a great advantage for the identification of peri-anastomotic PCa recurrence. Further
data about the complementary role of 18F-FACBC and MRI are required for the assessment of
prostatic bed recurrence, at different PSA levels.
5. The recurrence in the extra-prostatic site may be assessed by 18F-FACBC PET/CT with a moderate
sensitivity and specificity, independently from the PSA levels. However, the correlation with PSA
kinetics is warranted in a selected large cohort of patients, thus testing the final impact on the
patient management.
6. Despite some articles have defined a potential impact of 18F-FACBC PET/CT on therapeutic
management, there is still a lack information with regard to its role in radiotherapy planning and
other adapted therapy.
5. Future Researches
More data about the correlation between the detection rate of 18F-FACBC PET/CT or PET/MRI and
the PSA kinetics are warranted, particularly by a site and lesion-based analysis. The complementary
role of 18F-FACBC PET/CT and mpMRI for the evaluation of the prostatic bed should be largely
explored. A head-to-head comparison with 18F-Choline would be used in order to definitely assess its
advantages in clinical routine. Data about the utility of 18F-FACBC PET/CT in patients undergoing
or not hormonal therapy are required. The evaluation of response to therapy (chemotherapy or
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new hormonal agents) by 18F-FACBC PET/CT should be assessed. Finally, additional data about the
effect of 18F-FACBC PET/CT on patient management is required, by considering both PSA levels and
histopathological PCa characteristics.
6. Conclusions
18F-FACBC PET/CT seems to be promising in recurrent PCa, particularly for the evaluation
of the prostatic bed. However, additional studies are mandatory in order to evaluate its utility in
clinical routine.
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